Cidara Therapeutics (CDTX)
(Delayed Data from NSDQ)
$20.92 USD
-0.27 (-1.27%)
Updated Jan 14, 2025 04:00 PM ET
After-Market: $20.84 -0.08 (-0.38%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth A Momentum F VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
CDTX 20.92 -0.27(-1.27%)
Will CDTX be a Portfolio Killer in January?
Zacks Investment Research is releasing its prediction for CDTX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CDTX
Cidara Therapeutics (CDTX) Just Flashed Golden Cross Signal: Do You Buy?
Cytokinetics (CYTK) Reports Q1 Loss, Lags Revenue Estimates
CDTX: What are Zacks experts saying now?
Zacks Private Portfolio Services
TELA Bio, Inc. (TELA) Reports Q4 Loss, Tops Revenue Estimates
Emergent Biosolutions (EBS) Reports Q4 Loss, Tops Revenue Estimates
Codexis (CDXS) Tops Q4 Earnings and Revenue Estimates
Other News for CDTX
Cidara Therapeutics Announces Leadership Changes and Appointments
Twelve option delistings on December 23rd
Twelve option delistings on December 23rd
Cidara Therapeutics files to sell 7.04M shares of common stocks by selling shareholders
Cidara Therapeutics files to sell 7.04M shares of common stock for holders